Listening to the challenges faced by gummy manufacturers, Rousselot developed SiMoGel ™, a solution that enables faster, and hygienic gummy production in a starch-free environment. SiMoGel reduces the traditional 24-hour gelatin setting process to just 15 or 20 minutes.

Healthcare systems around the world face immense pressure, with costs soaring and populations growing larger and older. This makes the need for preventive solutions more urgent than ever.

Catarina Ferreira Da Silva explains her job title switch at Rousselot.

Imagine if we could test medicines on realistic models of human organs grown in the lab? 3D tissue and organ models or organoids are starting to play an important role in drug screening, and they may soon become a dominant tool in pharmaceutical drug discovery, development and testing according to a recent review published by Gerado-Nava et al. in Advanced Healthcare Materials .

Want to overcome manufacturing challenges in the growing functional gummies market? In this blog, discover how SiMoGel™ is changing the game.

Gelatin has a long and varied history in medicine, going back as far as 1834. Nowadays it’s a common material used in a number of pharmaceutical and biomedical applications around the world. With its well-established track record of versatility and reliability, it’s no surprise that gelatin is now playing an important role in groundbreaking regenerative medicine where, for example, it is used to produce hydrogels that support cell growth. In this article, we’re going to cover some of the key moments in gelatin’s pharma-medical history and take a look at how it’s used in pharma and medical applications.

Type the word ‘innovation’ into any search engine and the number of hits you get, within seconds, will exceed several billion. Innovation is a buzzword. So, if you’re as serious about it as we are, how do you take innovation to the next level? What does innovating innovation look like? How can we harness its power to add value in areas and in ways we are not yet today?

Dr Elien Gevaert , Principal Scientist at Rousselot Biomedical, wrote an article on the potential of gelatin to optimize cell line development workflows for the October 2022 edition of European Biopharmaceutical Review. Read her key insights from the article below.

Did you know that Rousselot ® Biomedical is more than just a supplier of medical gelatins and collagens? Find out how we can help you reduce time to market by supporting you at every stage of development, from ideation through to final product.

Dr. Jeff Daelman, Business Development Manager, Innovations, at Rousselot Biomedical, wrote an article on how to select the optimal gelatin-based biomaterial for successful cell culture for the May 2022 edition of Medical Device Developments. Read his key insights from the article below.